FI20090030A0 - Onkolyyttiset virukset - Google Patents

Onkolyyttiset virukset

Info

Publication number
FI20090030A0
FI20090030A0 FI20090030A FI20090030A FI20090030A0 FI 20090030 A0 FI20090030 A0 FI 20090030A0 FI 20090030 A FI20090030 A FI 20090030A FI 20090030 A FI20090030 A FI 20090030A FI 20090030 A0 FI20090030 A0 FI 20090030A0
Authority
FI
Finland
Prior art keywords
oncolytic virus
oncolytic
virus
Prior art date
Application number
FI20090030A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Akseli Eetu Hemminki
Otto Hemminki
Vincenzo Cerullo
Sari Pesonen
Gerd Bauerschmit
Original Assignee
Akseli Eetu Hemminki
Vincenzo Cerullo
Sari Pesonen
Otto Hemminki
Gerd Bauerschmit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akseli Eetu Hemminki, Vincenzo Cerullo, Sari Pesonen, Otto Hemminki, Gerd Bauerschmit filed Critical Akseli Eetu Hemminki
Priority to FI20090030A priority Critical patent/FI20090030A0/fi
Publication of FI20090030A0 publication Critical patent/FI20090030A0/fi
Priority to FI20095751A priority patent/FI121574B/fi
Priority to KR1020117020181A priority patent/KR20110110371A/ko
Priority to US13/147,288 priority patent/US20120063995A1/en
Priority to BRPI1008159A priority patent/BRPI1008159A2/pt
Priority to EP10704194.9A priority patent/EP2391722B1/en
Priority to CA2750770A priority patent/CA2750770A1/en
Priority to CN2010800087768A priority patent/CN102325887A/zh
Priority to PCT/IB2010/050452 priority patent/WO2010086838A2/en
Priority to RU2011136280/10A priority patent/RU2011136280A/ru
Priority to SG2011055563A priority patent/SG173502A1/en
Priority to AU2010209334A priority patent/AU2010209334A1/en
Priority to JP2011547047A priority patent/JP2012516682A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI20090030A 2009-02-02 2009-02-02 Onkolyyttiset virukset FI20090030A0 (fi)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FI20090030A FI20090030A0 (fi) 2009-02-02 2009-02-02 Onkolyyttiset virukset
FI20095751A FI121574B (fi) 2009-02-02 2009-07-02 Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
JP2011547047A JP2012516682A (ja) 2009-02-02 2010-02-02 非Ａｄ５アデノウイルスベクター並びに前記に関連する方法および使用
BRPI1008159A BRPI1008159A2 (pt) 2009-02-02 2010-02-02 vetores adenovirais não-ad5 e métodos e usos relacionados aos mesmos
US13/147,288 US20120063995A1 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
KR1020117020181A KR20110110371A (ko) 2009-02-02 2010-02-02 비-Ａｄ5 아데노바이러스 벡터 및 이와 관련된 방법 및 용도
EP10704194.9A EP2391722B1 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
CA2750770A CA2750770A1 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
CN2010800087768A CN102325887A (zh) 2009-02-02 2010-02-02 非-Ad5腺病毒载体及与其相关的方法和用途
PCT/IB2010/050452 WO2010086838A2 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
RU2011136280/10A RU2011136280A (ru) 2009-02-02 2010-02-02 HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
SG2011055563A SG173502A1 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
AU2010209334A AU2010209334A1 (en) 2009-02-02 2010-02-02 Non-Ad5 adenoviral vectors and methods and uses related thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20090030A FI20090030A0 (fi) 2009-02-02 2009-02-02 Onkolyyttiset virukset

Publications (1)

Publication Number Publication Date
FI20090030A0 true FI20090030A0 (fi) 2009-02-02

Family

ID=40404558

Family Applications (2)

Application Number Title Priority Date Filing Date
FI20090030A FI20090030A0 (fi) 2009-02-02 2009-02-02 Onkolyyttiset virukset
FI20095751A FI121574B (fi) 2009-02-02 2009-07-02 Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20095751A FI121574B (fi) 2009-02-02 2009-07-02 Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä

Country Status (12)

Country Link
US (1) US20120063995A1 (enExample)
EP (1) EP2391722B1 (enExample)
JP (1) JP2012516682A (enExample)
KR (1) KR20110110371A (enExample)
CN (1) CN102325887A (enExample)
AU (1) AU2010209334A1 (enExample)
BR (1) BRPI1008159A2 (enExample)
CA (1) CA2750770A1 (enExample)
FI (2) FI20090030A0 (enExample)
RU (1) RU2011136280A (enExample)
SG (1) SG173502A1 (enExample)
WO (1) WO2010086838A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011306846B2 (en) 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
EP3461491B1 (en) * 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Enhanced adoptive cell therapy
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
CN104946602A (zh) * 2015-06-11 2015-09-30 华中科技大学同济医学院附属同济医院 具有肿瘤组织靶向性和抑癌基因修复性的重组溶瘤腺病毒Ad5-P16及其应用
EP3783032A1 (en) * 2016-09-12 2021-02-24 Targovax Oy Combining adenovirus and checkpoint inhibitors for treating cancer
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
CN110741081B (zh) * 2017-01-30 2024-07-23 埃皮辛特瑞柯斯公司 肿瘤选择性tata盒和caat盒突变体
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
WO2019246111A1 (en) * 2018-06-19 2019-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1646717A4 (en) * 2003-07-18 2006-12-20 Onyx Pharma Inc ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof

Also Published As

Publication number Publication date
KR20110110371A (ko) 2011-10-06
FI20095751A0 (fi) 2009-07-02
WO2010086838A3 (en) 2010-11-25
FI20095751L (fi) 2010-08-03
FI121574B (fi) 2011-01-14
RU2011136280A (ru) 2013-03-10
BRPI1008159A2 (pt) 2016-03-29
US20120063995A1 (en) 2012-03-15
WO2010086838A2 (en) 2010-08-05
EP2391722A2 (en) 2011-12-07
JP2012516682A (ja) 2012-07-26
SG173502A1 (en) 2011-09-29
CA2750770A1 (en) 2010-08-05
EP2391722B1 (en) 2014-06-11
CN102325887A (zh) 2012-01-18
AU2010209334A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
FIC20220003I1 (fi) Vosoritidi
NO2017023I2 (no) Venetoklaks
CY2015012I1 (el) Αναστολεις του ιου της ηπατιτιδας c
BRPI1007836A2 (pt) Inibidores do vírus c da hepatite
BRPI1008846A2 (pt) inibidores do vírus da hepatite c
BRPI1013393A2 (pt) inibidores do vírus da hepatite c
BRPI1014084A2 (pt) inibidores do vírus da hepatite c
HRP20151000T8 (hr) Antivirusni spojevi
HUE041436T2 (hu) Tal-effektor-közvetített DNS-módosítás
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
EP2671451A4 (en) VIRENINAKTIVATOR
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112010004249A5 (de) Spindelaktor
EP2446176A4 (en) CYLINDER SEAL
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BRPI1008070A2 (pt) tricianoboratos
DE112010004865T8 (de) Lamellennassreibkupplung
DK2506968T3 (da) Faujasit-zeolit
BRPI1010159A2 (pt) bistuti
ES1070429Y (es) Traspaleta mejorada
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
DE112010002351A5 (de) Klemmorrichtung

Legal Events

Date Code Title Description
FD Application lapsed